Cytori Therapeutics Inc (CYTX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2018||Chairman of the Board|
|2018||President and Chief Medical Officer|
|2018||Chief Executive Officer, Director|
|35||2015||Chief Financial Officer, Chief Accounting Officer, Vice President - Finance|
|60||2007||President , Asia Pacific|
- BRIEF-Cytori Therapeutics Common Stock To Begin Trading On Adjusted Basis On May 24
- BRIEF-Cytori Reports Q1 2018 Business And Financial Results
- BRIEF-Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin
- BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial
- BRIEF-Cytori Q4 Adjusted Loss Per Share $0.10